Antonio Orlacchio1, Fabrizio Chegai2, Silvia Roma2, Stefano Merolla2, Alessandra Bosa3, Simona Francioso3. 1. Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University Hospital "Tor Vergata", Viale Oxford 81, 00133, Rome, Italy. aorlacchio@uniroma2.it. 2. Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University Hospital "Tor Vergata", Viale Oxford 81, 00133, Rome, Italy. 3. Hepatology Unit, University Hospital "Tor Vergata", Rome, Italy.
Abstract
PURPOSE: To evaluate safety and efficacy of degradable starch microspheres (DSMs) TACE in a large clinical cohort of patients with unresectable HCC. MATERIALS AND METHODS: This is a single-center consecutive patients cohort study. The study was approved by local institutional ethics committee. Written informed consent was obtained. From December 2013 to March 2018, 137 cirrhotic patients with unresectable HCC were enrolled. For DSMs-TACE, a mixture of 4 mL of DSMs, 6 mL of non-ionic contrast and doxorubicin at a dose of 50 mg/m2 were used. Primary end point was long-term outcome, in terms of time to progression (TTP) and overall survival (OS). Secondary endpoints were: safety, liver toxicity, 1-month percentage of tumor necrosis according to the modified RECIST criteria. RESULTS: Two hundred and sixty-seven DSMs-TACE were performed in 137 HCC patients (33 patients in BCLC stage A, 84 patients in BCLC stage B, and 20 in stage C). Patients had a mean nodule number of 3.5 ± 1.2 (SD). Major complications were observed in 6.8% of cases. Post-embolization syndrome was common (101 patients 73.7%). According to mRecist criteria, a high objective response rate was obtained even after just one treatment (84.3% of patients showed complete response or partial response). The median TTP and OS after DSMs-TACE were 12 months and 36 months, respectively. OS at 6 months, 1 year, 2 and 3 years was 98%, 81.3%, 57.9%, 34.9%, respectively. CONCLUSION: DSMs-TACE is a safe and effective therapy for patients with HCC, allowing to obtain a good rate of OS with excellent local tumor control.
PURPOSE: To evaluate safety and efficacy of degradable starch microspheres (DSMs) TACE in a large clinical cohort of patients with unresectable HCC. MATERIALS AND METHODS: This is a single-center consecutive patients cohort study. The study was approved by local institutional ethics committee. Written informed consent was obtained. From December 2013 to March 2018, 137 cirrhoticpatients with unresectable HCC were enrolled. For DSMs-TACE, a mixture of 4 mL of DSMs, 6 mL of non-ionic contrast and doxorubicin at a dose of 50 mg/m2 were used. Primary end point was long-term outcome, in terms of time to progression (TTP) and overall survival (OS). Secondary endpoints were: safety, liver toxicity, 1-month percentage of tumor necrosis according to the modified RECIST criteria. RESULTS: Two hundred and sixty-seven DSMs-TACE were performed in 137 HCCpatients (33 patients in BCLC stage A, 84 patients in BCLC stage B, and 20 in stage C). Patients had a mean nodule number of 3.5 ± 1.2 (SD). Major complications were observed in 6.8% of cases. Post-embolization syndrome was common (101 patients 73.7%). According to mRecist criteria, a high objective response rate was obtained even after just one treatment (84.3% of patients showed complete response or partial response). The median TTP and OS after DSMs-TACE were 12 months and 36 months, respectively. OS at 6 months, 1 year, 2 and 3 years was 98%, 81.3%, 57.9%, 34.9%, respectively. CONCLUSION: DSMs-TACE is a safe and effective therapy for patients with HCC, allowing to obtain a good rate of OS with excellent local tumor control.
Authors: Joseph P Erinjeri; Husam M Salhab; Anne M Covey; George I Getrajdman; Karen T Brown Journal: J Vasc Interv Radiol Date: 2010-02-25 Impact factor: 3.464
Authors: Myeong Jun Song; Chung-Hwa Park; Jin Dong Kim; Hee Yeon Kim; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Ho Jong Chun; Byung Gil Choi; Hae Giu Lee Journal: Eur J Gastroenterol Hepatol Date: 2011-06 Impact factor: 2.566
Authors: Karen T Brown; Richard K Do; Mithat Gonen; Anne M Covey; George I Getrajdman; Constantinos T Sofocleous; William R Jarnagin; Michael I D'Angelica; Peter J Allen; Joseph P Erinjeri; Lynn A Brody; Gerald P O'Neill; Kristian N Johnson; Alessandra R Garcia; Christopher Beattie; Binsheng Zhao; Stephen B Solomon; Lawrence H Schwartz; Ronald DeMatteo; Ghassan K Abou-Alfa Journal: J Clin Oncol Date: 2016-02-01 Impact factor: 44.544
Authors: Andreas Schicho; Philippe L Pereira; Michael Haimerl; Christoph Niessen; Katharina Michalik; Lukas P Beyer; Christian Stroszczynski; Philipp Wiggermann Journal: Oncotarget Date: 2017-08-07
Authors: Antonio Orlacchio; Fabrizio Chegai; Simona Francioso; Stefano Merolla; Serena Monti; Mario Angelico; Giuseppe Tisone; Lorenzo Mannelli Journal: Curr Med Imaging Rev Date: 2018-08
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo Journal: Infect Agent Cancer Date: 2021-07-19 Impact factor: 2.965
Authors: Vincenza Granata; Roberta Grassi; Roberta Fusco; Sergio Venanzio Setola; Andrea Belli; Mauro Piccirillo; Silvia Pradella; Marzia Giordano; Salvatore Cappabianca; Luca Brunese; Roberto Grassi; Antonella Petrillo; Francesco Izzo Journal: Int J Environ Res Public Health Date: 2021-03-30 Impact factor: 3.390